Imeglimin
Metabolic / DiabetesAlso known as: Twymeeg
Mechanism
The first in a new class of diabetes drugs called "glimins" that work by improving how mitochondria (the energy factories inside your cells) function. Approved in Japan for type 2 diabetes. It's a small molecule, not technically a peptide, but included here for metabolic completeness. Uniquely targets the root cause of metabolic dysfunction — impaired mitochondrial energy production — which affects both insulin secretion and insulin sensitivity.
Technical detail
First-in-class "glimin" — small molecule (not a peptide) that targets mitochondrial bioenergetics. MW 155.2, orally bioavailable. Triple mechanism: (1) Enhances mitochondrial respiratory chain complex I activity in beta cells → restores glucose-stimulated insulin secretion (GSIS) by normalizing ATP/ADP ratio and KATP channel function, (2) Reduces hepatic gluconeogenesis by partially inhibiting complex I in hepatocytes (similar to metformin but distinct binding site) → decreased NADH oxidation → impaired lactate-to-pyruvate conversion, (3) Protects beta cells from apoptosis by reducing mitochondrial permeability transition pore (mPTP) opening and oxidative stress. Phase 3 TIMES trials (Japan, n=1,100+): HbA1c reduction of 0.46% as monotherapy (TIMES 1), additive to all existing diabetes drug classes (TIMES 2-3). Weight neutral. Low hypoglycemia risk. Dosing: 1000mg BID with meals. GI side effects (nausea, diarrhea) less frequent than metformin. Half-life ~5 hours. Not a peptide — included for completeness in the metabolic/diabetes therapeutic landscape as a novel mechanism complementary to GLP-1/GIP-based peptide therapies.
Effects
METABOLIC SYSTEM: Imeglimin is the first member of the glimin drug class — a novel oral antidiabetic that targets mitochondrial bioenergetics [pharmacological]. PRIMARY MECHANISM: Enhances mitochondrial Complex I (NADH:ubiquinone oxidoreductase) function without acting as a direct inhibitor or activator — rather, it optimizes electron transport chain efficiency, reducing excessive reactive oxygen species (ROS) production while maintaining ATP synthesis [in vitro, animal]. This is fundamentally different from metformin, which partially inhibits Complex I. PANCREATIC EFFECTS: Amplifies glucose-stimulated insulin secretion (GSIS) from pancreatic β-cells in a glucose-dependent manner — works only when glucose is elevated, minimizing hypoglycemia risk [in vitro, animal, RCT]. Protects β-cells from glucolipotoxicity-induced apoptosis by reducing mitochondrial oxidative stress [in vitro, animal]. Preserves β-cell mass and function over time — potential disease-modifying effect beyond glycemic control [animal, long-term clinical data pending]. HEPATIC: Reduces hepatic glucose production — partly by improving mitochondrial function in hepatocytes, reducing the energy drive for gluconeogenesis [animal]. Improves hepatic insulin sensitivity [animal, clinical]. SKELETAL MUSCLE: Enhances insulin-stimulated glucose uptake by improving mitochondrial function in myocytes, restoring oxidative capacity [animal]. Reduces intramyocellular lipid accumulation [animal]. ENDOTHELIAL/CARDIOVASCULAR: Protects endothelial cells from hyperglycemia-induced oxidative damage by reducing mitochondrial ROS [in vitro]. Early data suggests improved endothelial function markers [clinical, small studies]. May reduce diabetic microvascular complications through mitochondrial protection [theoretical, animal]. COMPLEMENTARY TO METFORMIN: Because imeglimin optimizes Complex I function while metformin partially inhibits it, they work through distinct and potentially complementary mechanisms — additive glycemic benefit without mechanistic redundancy [pharmacological rationale, RCT].
Practitioner Guide
ADMINISTRATION: Oral tablet, 1000 mg twice daily with meals (morning and evening). No dose titration required — start at the full dose. Available as Twymeeg® in Japan (approved June 2021 by PMDA). Not yet approved by FDA or EMA (as of early 2026). CURRENT AVAILABILITY: Japan only. Prescribed by endocrinologists and primary care physicians for type 2 diabetes. International availability depends on ongoing regulatory submissions. POSITIONING IN T2D TREATMENT: In Japanese guidelines, imeglimin can be used as monotherapy or add-on to existing antidiabetic regimens including metformin, DPP-4 inhibitors, SGLT2 inhibitors, sulfonylureas, and insulin. The complementary mechanism with metformin is a key selling point — adding imeglimin to metformin provides additional HbA1c reduction of ~0.5-0.6% without increasing hypoglycemia or GI side effects [RCT — TIMES trials]. COMPARISON TO METFORMIN: Both target mitochondria but differently. Metformin: partial Complex I inhibitor → activates AMPK → reduces hepatic glucose output. Imeglimin: Complex I optimizer → reduces ROS → improves GSIS + hepatic/muscle insulin sensitivity. Metformin causes GI side effects (diarrhea, nausea) via intestinal serotonin release; imeglimin has a much milder GI profile. Metformin does not directly enhance insulin secretion; imeglimin does (glucose-dependently). They can be used together. GLYCEMIC EFFICACY: Monotherapy HbA1c reduction: ~0.5-0.7% from baseline ~7.5-8.0%. Comparable to DPP-4 inhibitors but via a completely different mechanism. Add-on to metformin: additional ~0.5-0.6% reduction. MONITORING: HbA1c every 3 months. Fasting glucose. No specific organ monitoring required based on current safety data. Renal function (standard for all diabetes medications). SIDE EFFECTS: Generally well-tolerated. Most common: nausea (mild, usually transient), diarrhea (less frequent than metformin). No hypoglycemia as monotherapy. No weight gain (weight-neutral). No lactic acidosis risk (unlike metformin — imeglimin does not inhibit Complex I). DRUG INTERACTIONS: No significant interactions identified in clinical trials. Compatible with all major antidiabetic drug classes.
Research Summary
TIER 1: TIMES 1 (Dubourg et al., 2021) — Phase III RCT in Japanese T2D patients: imeglimin 1000 mg BID monotherapy reduced HbA1c by 0.56% vs. placebo at 24 weeks. TIMES 2 — Phase III: imeglimin add-on to existing diabetes medications showed significant HbA1c reductions across all combination groups. TIMES 3 — long-term (52-week) safety and efficacy open-label extension. PMDA-approved June 2021 (Twymeeg®) — first-in-class approval. TIER 2: Preclinical mechanistic studies (Vial et al., 2015; Fouqueray et al., 2013): characterization of mitochondrial Complex I optimization and ROS reduction. β-cell protection studies in vitro and in animal models. Reviews of the glimin drug class and mitochondrial targeting in diabetes (Hallakou-Bozec et al., 2021). Phase IIb dose-finding studies in Caucasian populations (Poxel-sponsored). Pharmacokinetic studies establishing the 1000 mg BID dose. TIER 3: Japanese post-marketing surveillance data (emerging). Endocrinologist case series from Japanese clinical practice. Expert commentary on imeglimin's position in the T2D treatment landscape. Conference presentations on cardiovascular and renal outcome data (preliminary). KEY FINDINGS: Imeglimin represents a genuinely novel mechanism for type 2 diabetes — mitochondrial optimization rather than the traditional targets (insulin secretion, insulin sensitivity, renal glucose excretion). The complementary mechanism with metformin is pharmacologically elegant. Efficacy is moderate (comparable to DPP-4 inhibitors) but the safety profile is clean. The potential for β-cell preservation and disease modification is the most exciting long-term proposition. GAPS: No cardiovascular or renal outcomes trial (CVOT/RENAL — the modern requirement for diabetes drugs). Western regulatory approval pending (FDA, EMA submissions anticipated). Long-term β-cell preservation in humans not proven (animal data only). Limited data in non-Japanese populations. ACTIVE TRIALS: Poxel conducting additional studies for international regulatory submissions. Post-marketing studies in Japan. Exploratory studies in NAFLD/NASH (mitochondrial mechanism relevant).